Peringkat dalam Saham
#22998
Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000,... Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000, focuses on developing innovative therapeutic solutions for primary mitochondrial diseases. Its pipeline includes KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions, and NV354, which is preparing for clinical studies targeting primary mitochondrial diseases specifically linked to Complex I deficiency. The company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for the treatment of traumatic brain injury. Abliva maintains strategic partnerships with entities such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The firm rebranded as Abliva AB (publ) in May 2020, having previously been known as NeuroVive Pharmaceutical AB (publ).
Harga Saham
$0.04959193
Terakhir disinkronkan: 2025-03-17
Kapitalisasi Pasar
$79.94M
Perubahan (1 hari)
13.49%
Perubahan (1 tahun)
0.00%
Perdagangan Abliva AB (publ) (ABLI)
Harga ABLI dengan kapitalisasi pasar B
Kapitalisasi pasar dari Abliva AB (publ)(ABLI)
Kapitalisasi Pasar: $79.94M
Per August 2026, Abliva AB (publ) memiliki kapitalisasi pasar sebesar $79.94M. Ini menjadikan Abliva AB (publ) sebagai perusahaan 22998th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Abliva AB (publ) dari 2008 hingga 2026
ABLI dibandingkan dengan 5 teratas stocks paling populer
| Harga ABLI |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.211T
|
+6,519,334.37%
|
|
|
|
|
$4.547T
|
+5,687,889.61%
|
|
|
|
|
$4.162T
|
+5,207,166.93%
|
|
|
|
|
$3.593T
|
+4,494,489.39%
|
|
|
|
|
$2.793T
|
+3,493,767.13%
|
